TITLE: Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression

Similar documents
CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

Fort Detrick, Maryland

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

Award Number: W81XWH

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Breast Tumor-Generated Type 1 Collagen Breakdown Fragments Act as Matrikines to Drive Osteolysis

CONTRACTING ORGANIZATION: Oregon Health & Science University Beaverton, OR 97006

Approved for public release; distribution unlimited

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Induction of Ephs/Ephrins-Mediated Tumor Cells-Endothelial Cells Repulsion as an Anti-Cancer Therapeutic Approach

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Page 1 AWARD NUMBER: W81XWH TITLE: A Novel Pleiotropic Anti-Inflammatory Drug to Reduce ARDS Incidence. PRINCIPAL INVESTIGATOR: Gary Nieman

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, TX 77030

TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

Award Number: W81XWH

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Detection of Prostate Cancer Progression by Serum DNA Integrity

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer

La Jolla, CA Approved for Public Release; Distribution Unlimited

Award Number: W81XWH TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis

TITLE: Investigating the Role of TBX2 in the Inhibition of Senescence in Prostate Cancer

TITLE: Systemic Oncolytic Cytokine HSV Therapy of Prostate Cancer. CONTRACTING ORGANIZATION: Massachusetts General Hospital Boston, MA

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1. Palo Alto, CA 94304

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

TITLE: Post-Traumatic Headache and Psychological Health: Mindfulness Training for Mild Traumatic Brain Injury

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

TITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Approved for public release; distribution unlimited

TITLE: Targeted Eradication of Prostate Cancer Mediated by Engineered Mesenchymal Stem Cells

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center Nashville, TN

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Award Number: W81XWH TITLE: "Longitudinal Study of a Novel Performance-based Measure of Daily Function."

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis

CONTRACTING ORGANIZATION: Rush University Medical Center Chicago, IL 60612

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: The Role Of Alternative Splicing In Breast Cancer Progression

Award Number: W81XWH TITLE: CYP1B1 Polymorphism as a Risk Factor for Race-Related Prostate Cancer

TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.

TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention

TITLE: Treatment of Dengue Virus Infection with Repurposed Pharmaceuticals that Inhibit Autophagy

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

AD (Leave blank) PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

TITLE: Maximizing Energy After Traumatic Brain Injury: A Novel Intervention

RECIPIENT: Lankenau Institute for Medical Research, Wynnewood, PA 19096

TITLE: "Impact of Obesity on Tamoxifen Chemoprevention in a Model of Ductal Carcinoma in Situ"

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: The Role of Constitutively Active Prolactin Receptors in the Natural History of Breast Cancer

CONTRACTING ORGANIZATION: UNIVERSITY OF ILLINOIS Chicago, IL 60612

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine, New York, NY 10029

TITLE: TREATMENT OF ENDOCRINE-RESISTANT BREAST CANCER WITH A SMALL MOLECULE C-MYC INHIBITOR

TITLE: Proteomic Mapping of the Immune Response to Gluten in Children with Autism

TITLE: Prostate Expression Databases: Gene Expression Resources for Comparative Studies of Prostate Carcinogenesis

TITLE: Prazosin for Treatment of Patients With PTSD and Comorbid Alcohol Dependence

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

Transcription:

AD Award Number: W81XWH-07-1-0253 TITLE: Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression PRINCIPAL INVESTIGATOR: Pal Gooz, M.D. CONTRACTING ORGANIZATION: Medical University of South Carolina Charleston, SC 29425 REPORT DATE: April 2008 TYPE OF REPORT: Annual PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE Form Approved OMB No. 0704-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE 14-04-2008 2. REPORT TYPE Annual 3. DATES COVERED 15 MAR 2007-14 MAR 2008 4. TITLE AND SUBTITLE 5a. CONTRACT NUMBER Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression 5b. GRANT NUMBER W81XWH-07-1-0253 5c. PROGRAM ELEMENT NUMBER 6. AUTHOR(S) Pal Gooz, M.D. 5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER Email: 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Medical University of South Carolina Charleston, SC 29425 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SPONSOR/MONITOR S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT In 30 to 70 % of systemic sclerosis patients, the disease progresses to the lungs and internal organs. This lung fibrosis (i.e. the overexpression of collagen) is the major cause of morbidity and mortality in scleroderma. The overexpression of collagen is accompanied by the overexpression of other extracellular matrix molecules including hyaluronic acid (HA). To evaluate the possibility that HA regulates collagen expression, we treated lung fibroblasts with HA oligomers (fragments of HA that block HA binding to its cell surface receptors CD44, TLR2, and TLR4). Both HA oligomers and lipopolysaccharide (LPS, another TLR2 and TLR4 ligand) had major effects on collagen expression. In addition, HA oligomers affected the expression of the collagen-degrading enzyme MMP-2. These observations open up the possibility that reagents that affect signaling cascades initiated by HA or LPS will have therapeutic value in inhibiting the progression of lung fibrosis in human patients. 15. SUBJECT TERMS Collagen, hyaluronic acid, lung fibrosis, CD44, TLR2, TLR4 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT a. REPORT U b. ABSTRACT U 18. NUMBER OF PAGES c. THIS PAGE U UU 7 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code) Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std. Z39.18

Table of Contents Page Introduction..... 4 Body.. 4 Key Research Accomplishments... 6 Reportable Outcomes 6 Conclusion 6 References. 7 Appendices 7 3

INTRODUCTION Systemic scleroderma is a debilitating disease that affects approximately 100,000 people in the US, mostly women, and is characterized by immune system activation, autoimmunity, smallvessel vasculopathy, and skin fibrosis. In 30 to 70 % of patients, the disease progresses to the lungs and other internal organs. Lung fibrosis (i.e. the excessive accumulation of extracellular matrix [ECM] proteins, particularly collagen I) is the major cause of morbidity and mortality in scleroderma. The overexpression of collagen I in fibrotic lung tissue is accompanied by the overexpression of other ECM molecules (e.g. the glycosaminoglycan hyaluronic acid [HA] and the proteins periostin, tenascin-c, and versican) and by inflammatory cell infiltration. In the simplest viewpoint, it is possible that tissue damage leads to inflammatory cell infiltration and that in turn cytokines produced by inflammatory cells and damaged tissue promote the expression of collagen I and other ECM molecules. However, it is more likely that the regulation of these processes (inflammatory cell infiltration, collagen I expression, expression of other ECM molecules) are intertwined in a complex manner. For example, HA is known to promote inflammatory cell infiltration into damaged lung tissue (1) and our Preliminary Studies suggest that it regulates collagen expression by lung fibroblasts. Periostin has been shown to regulate collagen expression in other systems (2). Therefore, our long-term goal is to determine how modulation of the expression and function of ECM molecules such as HA and periostin will alter the progression of lung fibrosis by affecting the expression of collagen I by lung fibroblasts and by affecting inflammatory cell infiltration. These experiments will be performed in both in vitro and in vivo model systems. In vitro experiments will be performed using cultured lung fibroblasts. In vivo experiments will be performed using mice in which lung fibrosis is induced by intratracheal delivery of bleomycin. While bleomycin may not be a perfect model for human diseases, it is a very convenient and reliable way of inducing lung fibrosis in mice and is the best available model for scleroderma lung disease because both bleomycin treatment and scleroderma lung disease produce inflammatory alveolitis and overproduction of collagen and other ECM molecules. BODY Our research accomplishments in the first year of the project were limited by time lost due to a change in Principal Investigator (PI). Little more than 2 months was available to perform research after the change was completed. Fortunately, essentially no funds were spent prior to the change in PI. Therefore, we are pleased with the progress that we have made in this short time period and we are confident that we have sufficient resources available to complete the research described in the Work Plan within the three year tenure of this grant. HA is composed of long chains of repeating N-acetyl-glucosamine-D-glucuronic acid disaccharides that can easily reach molecular weight of > than 1 x 10 6 daltons. HA binds to other extracellular matrix molecules and to cell surface receptors including CD44, TLR2, and TLR4 (1). The binding of HA to proteins can be inhibited by the presence of HA oligomers (short HA segments with a molecular weight of about 2 x 10 3 daltons (3). In the Preliminary Studies reported in the grant proposal leading to this project, using primary cultures of normal adult human lung fibroblasts (NLF), we observed that HA oligomers inhibited collagen expression. Because the use of these primary cultures is sometimes criticized due to variations between strains isolated from different individuals, we chose to initiate our experiments using the human embryonic lung fibroblast cell line MRC-5. Experiments were performed in the absence of added TGFβ to simulate baseline conditions in normal lung tissue and in the presence of added TGFβ to simulate the conditions in fibrotic lung tissue where high levels of TGFβ are present and promote the expression of ECM molecules. 4

As in our experiments using NLF, the addition of HA oligomers had a profound effect on collagen expression by MRC-5 cells. However, whereas HA oligomers inhibited the baseline expression of collagen by NLF, they promoted the baseline expression of collagen by MRC-5 cells three-fold (Fig. 1). Interestingly, HA oligomers had no effect or possibly a small inhibitory effect on TGFβ-stimulated collagen expression by MRC-5 cells. While the data shown in Fig. 1 was obtained using cells incubated in the presence of HA oligomers for 48 hours, these effects were already apparent following a 6-hour incubation. In summary, given that the use of HA oligomers to block HA signaling promotes collagen expression by MRC-5 cells in the absence of added TGFβ and has little effect on collagen expression by cells treated with TGFβ, these results suggest that HA itself inhibits collagen expression by MRC-5 cells in the absence of TGFβ and has little effect on collagen expression by MRC-5 cells in the presence of TGFβ. Figure 1. Effects of HA Oligomers and LPS on Collagen and MMP-2 Expression by MRC-5 Cells. Cell cultures were initiated by passaging 2 x 10 5 cells into each well of several 6-well plates. After 24 hours, serum-containing medium was replaced with serum-free medium supplemented with no addition (Con), 5 micrograms per ml of HA oligomers (HA5), 25 micrograms per ml of HA oligomers (HA25), or 0.5 micrograms per ml of lipopolysaccharide (LPS) in the presence or absence of 4 nanograms per ml of TGFβ. After 48 h, the medium and cell layer were harvested. (A) Detection of collagen I, MMP-2 and actin. Collagen in the medium and actin (loading control) in the cell layer were detected by Western blotting. MMP-2 in the medium was detected by gelatin zymography. Collagen and MMP-2 in the cell layer are not shown because the level of these proteins in the cell layer was < 10 % of their level in the medium. (B) Quantification of A. The relative level of each protein in each sample was quantified by densitometry. The levels of collagen and MMP-2 in each sample were normalized against the actin levels, the normalized level of collagen and MMP-2 in the Baseline sample (i.e. no added TGFβ) with no addition was defined as 1 arbitrary unit. The data presented here are representative results from one of three experiments in which similar results were obtained. HA oligomers were Catalog Number HYA-OLIGO10EF-1 from Hyalose (Oklahoma City, OK). LPS was Product Number L 4391 from Sigma (St. Louis, MO). 5

While TLR2 and TLR4 serve as cell surface HA receptors, they are better known as LPS receptors (1). Therefore, we also examined the effect of LPS on collagen expression by MRC-5 cells. Interestingly, like HA oligomers, LPS promoted the baseline expression of collagen (Fig. 1). However, unlike HA oligomers, LPS inhibited TGFβ-induced collagen expression (Fig. 1). The level of collagen in tissues is dependent both on the expression of collagen and the degradation of collagen by MMPs and other enzymes. Therefore we examined the effects of HA oligomers and LPS on the expression of MMP-2. HA oligomers increased the baseline expression of MMP-2, but had little or no effect on TGFβ-induced MMP-2 expression (Fig. 1). LPS had relatively little effect on MMP-2 expression in the presence or absence or TGFβ. Our results are summarized in Table 1. It is noteworthy that the inhibitory effect of HA on collagen expression may be blunted by its inhibitory effect on collagen degradation mediated by MMP-2. Table 1. Effects of HA and LPS on Col I and MMP-2 Expression by MRC-5 Lung Fibroblasts Baseline (No TGFβ). + TGFβ. HA LPS HA LPS Col I Inhibits Promotes Little Effect Inhibits MMP-2 Inhibits Little Effect Little Effect Little Effect Because HA oligomers inhibit the function of HA (3), we assume that the function of HA is opposite to the effects that we observed with HA oligomers. Changes of 30 % or less were considered to be Little Effect. The results of these experiments and the possible discrepancy between results obtained with NLF and MRC-5 cells highlights the importance of repeating these experiments with NLF and with lung fibroblasts derived from the fibrotic lung tissue of scleroderma patients (SLF). If MRC-5 cells differ from NLF and if MRC-5 cells treated with TGFβ differ from SLF, it will become all the more important to evaluate how these various cell types differ in their expression of HA, CD44, TLR2, and TLR4 and to determine how modulating the expression or function of HA and its receptors affects collagen expression in these cells. A particularly attractive approach to this problem would be to isolate lung fibroblasts from control mice and knockout mice lacking CD44, TLR2, and TLR4. KEY RESEARCH ACCOMPLISHMENTS We have observed that: HA oligomers promote baseline collagen expression in MRC-5 cells LPS promotes baseline collagen expression in MRC-5 cells HA oligomers promote baseline MMP-2 expression in MRC-5 cells LPS inhibits TGFβ-induced collagen expression in MRC-5 cells REPORTABLE OUTCOMES None. CONCLUSION The observation that HA oligomers affect the expression of collagen and MMP-2 by lung fibroblasts supports the idea that the expression of one ECM molecule can regulate the expression of another ECM molecule and raises the possibility of using fragments of ECM 6

molecules or inhibitors or activators of ECM molecule-initiated signaling pathways as therapeutic agents. The possibility that HA oligomers may promote collagen expression in some types of lung fibroblasts while inhibiting collagen expression in other types of lung fibroblasts suggests many ways in which our Work Plan needs to be refined. It will be critical in various cell types to compare both the baseline and TGFβ-induced levels of expression of HA and the HA receptors CD44, TLR2, and TLR4 and to use several different approaches to determine how modulating the expression or function of HA and its receptors affects collagen expression. A particularly attractive approach to this problem would be to isolate lung fibroblasts from control mice and knockout mice lacking CD44, TLR2, and TLR4. In summary, our observations that HA oligomers and LPS can regulate collagen expression in lung fibroblasts opens up the possibility that reagents that activate or block the signaling cascades initiated by HA or LPS will have therapeutic value in inhibiting the progression of lung fibrosis in human patients. REFERENCES 1. Jiang, D., Liang, J., Fan, J., Yu, S., Chen, S., Luo, Y., Prestwich, G.D., Mascarenhas, M.M., Garg, H.G., Quinn, D.A., et al. 2005. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 11:1173-1179. 2. Norris, R.A., Moreno-Rodriguez, R.A., Sugi, Y., Hoffman, S., Amos, J., Hart, M.M., Potts, J.D., Goodwin, R.L., and Markwald, R.R. 2008. Periostin regulates atrioventricular valve maturation. Dev Biol 316:200-213. 3. Ghatak, S., Misra, S., and Toole, B.P. 2005. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem 280:8875-8883. APPENDICES None. 7